Abstract Details

Title A Brain Care Score for Dementia and Stroke: Data from the UK Biobank Cohort

Topic General Neurology

Presentation(s) P10 - Poster Session 10 (11:45 AM-12:45 PM)

Poster/Presentation
Number 15-002

Objective We aimed to assess the associations of the Brain Care Score (BCS) with risk of incident dementia and stroke.

Background The 21-point BCS was developed through a modified Delphi process in partnership with practitioners and patients to promote behavior changes and lifestyle choices in order to sustainably reduce the risk of dementia and stroke.

Design/Methods

The BCS was derived from the UK Biobank (UKB) baseline evaluation for participants aged 40–69 years, recruited between 2006–2010. Associations of BCS and risk of subsequent incident dementia and stroke were estimated using Cox proportional hazard regressions, adjusted for sex assigned at birth and stratified by age groups at baseline.

Results

The BCS (median: 12; IQR:11–14) was derived for 398,990 UKB participants (mean age: 57; females: 54%). There were 5,354 incident cases of dementia and 7,259 incident cases of stroke recorded during a median follow-up of 12.5 years. A five-point higher BCS at baseline was associated with a 59% (HR: 0.41, 95%CI: 0.28–0.60) lower risk of dementia among participants aged <50. Among those aged 50–59, the figure was 32% (HR: 0.68, 95%CI: 0.58–0.80) and 8% (HR: 0.92, 95%CI: 0.86–0.98) for those aged >59 years. A five-point higher BCS was associated with a 48% (HR: 0.52, 95%CI: 0.44–0.61) lower risk of stroke among participants aged <50, 52% (HR: 0.48, 95%CI: 0.44–0.53) among those aged 50–59, and 33% (HR: 0.67, 95%CI: 0.63–0.71) among those aged >59.

Conclusions

The BCS has clinically relevant and statistically significant associations with risk of dementia and stroke in approximately 0.4 million UK people. Future research includes investigating the feasibility, adaptability and implementation of the BCS for patients and providers worldwide.

Authors/Disclosures
Sanjula D. Singh, MD, PhD PRESENTER	Dr. Singh has nothing to disclose.
Tin Oreskovic (Big Data Institute, Nuffield Department of Population Health)	No disclosure on file
Sinclair Carr	No disclosure on file
Keren Papier (University of Oxford)	No disclosure on file
Megan Conroy (University of Oxford)	No disclosure on file
Jasper R. Senff, MD (McCance Center for Brain Health)	Dr. Senff has nothing to disclose.
Zeina N. Chemali, MD (Massachusetts General Hospital)	Dr. Chemali has nothing to disclose.
Leidys Gutierrez-Martinez, MD (Massachusetts General Hospital)	The institution of Dr. Gutierrez-Martinez has received research support from American Heart Association.
Livia Parodi	No disclosure on file
Ernst Mayerhofer, MD	Dr. Mayerhofer has nothing to disclose.
Sandro Marini, MD (Boston Medical Center)	Dr. Marini has nothing to disclose.
Courtney Nunley	No disclosure on file
Amy Newhouse (Massachusetts General Hospital)	No disclosure on file
An Ouyang	No disclosure on file
Bart Brouwers (Neurosurgeon Elisabeth-TweeSteden Hospital)	No disclosure on file
M. B. Westover, MD, PhD (MGH)	Dr. Westover has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Beacon Biosignals. Dr. Westover has stock in Beacon Biosignals. The institution of Dr. Westover has received research support from NIH. Dr. Westover has received publishing royalties from a publication relating to health care. Dr. Westover has a non-compensated relationship as a cofounder with Beacon Biosignals that is relevant to AAN interests or activities.
Cyprien Rivier, MD (Yale University)	Dr. Rivier has nothing to disclose.
Guido J. Falcone, MD (Yale School of Medicine)	The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.
Virginia J. Howard, PhD (University of Alabama At Birmingham)	The institution of Dr. Howard has received research support from NIH. The institution of an immediate family member of Dr. Howard has received research support from NIH.
George Howard, PhD (UAB School of Public Hlth)	Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer.
Aleksandra Pikula, MD	The institution of Dr. Pikula has received research support from CIHR.
Sarah Ibrahim	No disclosure on file
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care)	Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Nirupama Yechoor, MD (MassGeneral Brigham)	Dr. Yechoor has nothing to disclose.
Ronald M. Lazar, PhD, FAHA, FAAN, FAAN (University of Alabama At Birmingham)	Dr. Lazar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DiaMedica Therapeutics Inc. . The institution of Dr. Lazar has received research support from National Institutes of Health. Dr. Lazar has received publishing royalties from a publication relating to health care.
Christopher D. Anderson, MD, PhD, FAAN (Brigham and Women's Hospital)	The institution of Dr. Anderson has received research support from Bayer AG. The institution of Dr. Anderson has received research support from American Heart Association. The institution of Dr. Anderson has received research support from National Institutes of Health. An immediate family member of Dr. Anderson has received publishing royalties from a publication relating to health care.
Gregory Fricchione (Massachusetts General Hospital)	No disclosure on file
Thomas Littlejohns (University of Oxford)	No disclosure on file
Jonathan Rosand, MD (Massachusetts General Hospital)	Dr. Rosand has received personal compensation for serving as an employee of Massachusetts General Hospital. Dr. Rosand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Rosand has received research support from NIH. The institution of Dr. Rosand has received research support from American Heart Association. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as a Peer reviewer with National Institutes of Health. Dr. Rosand has a non-compensated relationship as a Trustee with Columbia University that is relevant to AAN interests or activities.

��ɫ��

��ɫ��